Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 32011L0100

Commission Directive 2011/100/EU of 20 December 2011 amending Directive 98/79/EC of the European Parliament and of the Council on in-vitro diagnostic medical devices Text with EEA relevance

OJ L 341, 22.12.2011, p. 50–51 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

⏵This document has been published in a special edition(s) (HR)

Legal status of the document No longer in force, Date of end of validity: 25/05/2020; Implicitly repealed by 32017R0746

ELI: http://data.europa.eu/eli/dir/2011/100/oj

22.12.2011   

EN

Official Journal of the European Union

L 341/50

COMMISSION DIRECTIVE 2011/100/EU

of 20 December 2011

amending Directive 98/79/EC of the European Parliament and of the Council on in-vitro diagnostic medical devices

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in-vitro diagnostic medical devices (1), and in particular Article 14 thereof,

Whereas:

(1)

In accordance with Article 14(1)(a) of Directive 98/79/EC, the United Kingdom has requested that the Commission take the necessary measures to add ‘Variant Creutzfeldt-Jakob disease’ (vCJD) assays to List A of Annex II to that Directive.

(2)

In order to ensure the highest level of health protection and ensure that the conformity of vCJD assays with the essential requirements set out in Annex I to Directive 98/79/EC is verified by notified bodies, vCJD assays for blood screening, diagnosis and confirmation should be added to List A of Annex II to Directive 98/79/EC.

(3)

The measures provided for in this Directive are in accordance with the opinion of the Committee set up by Article 6(2) of Council Directive 90/385/EEC (2) and referred to in Article 7(1) of Directive 98/79/EC,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex II to Directive 98/79/EC is amended in accordance with the Annex to this Directive.

Article 2

1.   Member States shall adopt and publish the laws, regulations and administrative provisions necessary to comply with this Directive by 30 June 2012 at the latest. They shall forthwith communicate to the Commission the text of those provisions.

Member States shall apply those provisions from 1 July 2012.

When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2.   Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

This Directive shall enter into force on the 20th day following its publication in the Official Journal of the European Union.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, 20 December 2011.

For the Commission

The President

José Manuel BARROSO

(1)   OJ L 331, 7.12.1998, p. 1.

(2)   OJ L 189, 20.7.1990, p. 17.

ANNEX

The following indent is added at the end of List A of Annex II to Directive 98/79/EC:

‘—

Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening, diagnosis and confirmation.’
Top